VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BHST
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
BHSTBioHarvest Sciences Inc. Common Stock
$2.96$51M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

BHST logoBioHarvest Sciences Inc. Common Stock(BHST)Earnings, Financials & Key Ratios

BHST•NASDAQ
$2.96
Price updated Jul 7, 2026
SectorBasic MaterialsIndustryAgricultural InputsSub-IndustryConsumer and specialty ag systems
AboutBioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.Show more
  • Revenue$35M+37.0%
  • EBITDA-$4M+31.1%
  • Net Income-$11M+13.8%
  • EPS (Diluted)-0.60+25.0%
  • Gross Margin59.34%+7.2%
  • EBITDA Margin-11.45%+49.7%
  • Operating Margin-16.16%+41.8%
  • Net Margin-32.27%+37.1%
  • ROE-83.17%+91.4%

BHST Price & Volume

BioHarvest Sciences Inc. Common Stock (BHST) stock price & volume — 10-year historical chart

Loading chart...

Decelerating Revenue Growth Amid Persistent Cash Burn

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Decelerating
Profitability:Negative
Financial:Mixed
Cash Flow:Burning
Primary Risk:Persistent Operating Cash Burn

Key Thesis Takeaways

  • BioHarvest Sciences is currently navigating a challenging transition from high-growth commercialization to operational sustainability, as evidenced by revenue growth slowing to 8.2% in 2026Q1.
  • While the company has successfully scaled its proprietary bioreactor infrastructure, reflected in a $16.8M net PPE position, the lack of positive operating leverage remains a primary concern.
  • Investors should monitor the company's ability to bridge the gap between its 59.2% gross margin and the persistent net losses that totaled $2.6 million in the most recent quarter.

Verdict Logic

while the company has improved its current ratio to 2.96, the persistent net loss of $2.6 million in 2026Q1 and the lack of positive operating leverage suggest significant execution risk remains.

BHST Growth Metrics

BioHarvest Sciences Inc. Common Stock (BHST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years144.37%
3 Years84.46%
TTM26.9%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-31.93%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-24%

Return on Capital

10 Years-194.35%
5 Years-190.94%
3 Years-128.18%
Last Year-21.98%

BHST Recent Earnings

BioHarvest Sciences Inc. Common Stock (BHST) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 4/12 qtrs (50%)●Beat Revenue 2/12 qtrs (29%)
Q2 2026Latest
May 14, 2026
Metric
Actual
Est
EPS
$0.10+9.1%
$0.11
Rev
—
$9M
Q2 2026
Mar 31, 2026
Metric
Actual
Est
EPS
$0.10+4.8%
$0.10
Rev
$9M-1.5%
$9M
Q4 2025
Nov 13, 2025
Metric
Actual
Est
EPS
$0.14+0.0%
$0.14
Rev
$9M-1.0%
$9M
Q3 2025
Aug 11, 2025
Metric
Actual
Est
EPS
$0.15-36.4%
$0.11
Rev
$9M-6.0%
$9M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 14, 2026
$0.10vs $0.11+9.1%
—vs $9M
Q2 2026Mar 31, 2026
$0.10vs $0.10+4.8%
$9Mvs $9M-1.5%
Q4 2025Nov 13, 2025
$0.14vs $0.14+0.0%
$9Mvs $9M-1.0%
Q3 2025Aug 11, 2025
$0.15vs $0.11-36.4%
$9Mvs $9M-6.0%
Based on last 12 quarters of dataView full earnings history →

Latest BHST News

Recent stock market news and headlines for BioHarvest Sciences Inc. Common Stock (BHST)

Newsfile Corp·Jun 18, 2026
BioHarvest Sciences to Present at the 2026 BIO International Convention

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will present at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, California. Presentation Details: Session: Company Presentation Date/Time: Wednesday, June 24, 11:45 AM Location: Theater 3 BioHarvest Sciences' presentation will showcase its proprietary Botanical Synthesis™ platform, which enables the production of plant-derived compounds with pharmaceutical-grade precision, consistency, and commercial scalability, opening new possibilities in drug discovery, active pharmaceutical ingredients, and next-generation therapeutics.

Peers Comparison

Key metrics vs top competitors for BioHarvest Sciences Inc. Common Stock (BHST)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
BHST logoBHSTBioHarvest Sciences Inc. Common StockCurrent
$2.96$51.29M-4.9337%-32.27%-83.17%—
NXRT logoNXRTNexPoint Residential Trust, Inc.
$28.94$734.45M-22.97-3.24%-12.67%-10.13%—
GFAI logoGFAIGuardforce AI Co., Limited
$0.39$8.55M-1.30-3.07%-17.49%-40.41%—
SIGA logoSIGASIGA Technologies, Inc.
$3.67$263.23M11.12-31.8%21.61%10.62%—
XTLB logoXTLBXTL Biopharmaceuticals Ltd.
$2.98$327.88K-0.31—-227.72%-25.53%—
LWAY logoLWAYLifeway Foods, Inc.
$29.32$447.99M32.9413.74%6.54%17.76%—

Compare BHST vs Peers

BioHarvest Sciences Inc. Common Stock (BHST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NXRT

Most directly comparable listed peer for BHST.

Scale Benchmark

vs HALO

Larger-name benchmark to compare BHST against a more recognizable public peer.

Peer Set

Compare Top 5

vs NXRT, GFAI, SIGA, XTLB

Get notified when BHST posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

BHST Frequently Asked Questions

BioHarvest Sciences Inc. Common Stock (BHST) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is BioHarvest Sciences Inc. Common Stock's revenue?

BioHarvest Sciences Inc. Common Stock (BHST) reported $35.2M in revenue for fiscal year 2025.

How fast is BioHarvest Sciences Inc. Common Stock growing?

BioHarvest Sciences Inc. Common Stock (BHST) grew revenue by 37.0% over the past year. This is strong growth.

Is BHST profitable?

BioHarvest Sciences Inc. Common Stock (BHST) reported a net loss of $11.4M for fiscal year 2025.

Dividend & Returns
What is BHST's return on equity?

BioHarvest Sciences Inc. Common Stock (BHST) has a return on equity (ROE) of -83.2%. Negative ROE indicates the company is unprofitable.

What is BioHarvest Sciences Inc. Common Stock's free cash flow?

BioHarvest Sciences Inc. Common Stock (BHST) had negative free cash flow of $9.7M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in BHST back in 2013?

Total return calculator · dividends reinvested · 13+ years of data

See returns →